Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Research and development partners payable, current by Quarter
Research and development partners payable, current ($M) ($M)
Moderna Research and development partners payable, current: $14M in Q2 2026.
Latest, Q2 2026
14
Period ended Jun 30, 2026
Change on a year earlier
–
0 in Q2 2025
History
8 quarters
Since Q4 2023
Sources
7
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 4 (Collaboration Agreements).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Research and development partners payable, current ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 14 | – | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 0 | – | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 43 | -25.9% | Form 10-Q (filed 2026-07-31) ↗ |
| Q3 2025 | Sep 30, 2025 | 0 | – | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 0 | – | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2025 | Mar 31, 2025 | 0 | – | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 58 | – | Form 10-K (filed 2026-02-20) ↗ |
| Q4 2023 | Dec 31, 2023 | 0 | – | Form 10-K (filed 2025-02-21) ↗ |
Cite this data
StockData. (2026). Moderna Research and development partners payable, current ($M), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rd-liab-cur
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.